SRZN
SRZN
NASDAQ · Biotechnology

Surrozen Inc

$31.88
-0.76 (-2.33%)
Financial Highlights (FY 2026)
Revenue
5.64M
Net Income
-392,300,607
Gross Margin
—
Profit Margin
-6,960.8%
Rev Growth
-34.7%
D/E Ratio
—
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin — — 61.1% 61.1%
Operating Margin -1,210.6% -1,089.5% -7.9% -7.5%
Profit Margin -6,960.8% -6,612.7% -5.7% -7.5%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 5.64M 8.63M 49.01M 58.73M
Gross Profit — — 29.94M 35.88M
Operating Income -68,232,053 -94,069,926 -3,884,365 -4,377,578
Net Income -392,300,607 -540,855,616 -2,802,997 -4,374,334
Gross Margin — — 61.1% 61.1%
Operating Margin -1,210.6% -1,089.5% -7.9% -7.5%
Profit Margin -6,960.8% -6,612.7% -5.7% -7.5%
Rev Growth -34.7% -34.7% +7.4% -1.1%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 78.39M 78.23M
Total Equity — — 95.79M 82.86M
D/E Ratio — — 0.82 0.94
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -67,356,951 -98,022,523 -4,562,575 -6,395,991
Free Cash Flow — — -4,055,082 -5,438,545